Loading
Life sciences · Journal article
World Journal of Hepatology · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Metabolic dysfunction-associated steatotic liver disease is the most common chronic liver disease in youth, yet treatment response remains difficult to define as lifestyle therapy, anti-obesity pharmacotherapy, and metabolic and bariatric surgery produce changes across different biological domains.This narrative review examines histology, alanine aminotransferase, magnetic resonance imaging proton density fat fraction, elastography, serum biomarkers, body composition, cardiometabolic health, and patient-centered outcomes as candidate response endpoints.Diagnostic accuracy, cross-sectional severity, prognostic validity, longitudinal responsiveness, association with histological response, and validated thresholds for meaningful change are considered separately.Pediatric evidence remains strongest for repeated aminotransferases, growth-adjusted adiposity measures, and selected imaging approaches, but no single test defines response and normal aminotransferases do not exclude persistent steatohepatitis or fibrosis.Adult magnetic resonance imaging and drug-trial thresholds are informative but cannot be adopted uncritically in children.Loss of lean mass should also not be equated with sarcopenia without evidence of low muscle quantity and impaired strength or function.A practical three-tier framework is proposed: Minimum clinical assessment, specialistcenter assessment, and research endpoints.The proposed tiers and reassessment intervals are pragmatic author guidance, not validated pediatric standards, and require prospective validation.Until pediatric longitudinal thresholds are validated, response assessment should be multidimensional, treatment-specific, growth-aware, patientcentered, and adapted to feasibility and equity.